LXEO logo

LEXEO THERAPEUTICS INC

LXEONASDAQ
🏆 #3403 by market capEarnings Nov 9US Equity
$3.33▲ $0.19 (+6.05%)
Latest quote
🔔
Track LXEO
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 6.0%
7d▲ 15.0%
14d▲ 21.1%
30d▼ 2.9%
ytd▼ 66.4%
1y▼ 66.4%
🏦Market Cap
$273M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
40
Weak

Trading Snapshot

Day Range
$3.18 – $3.33
52-Week Range
$2.55 – $10.99
Volume (shares)
5,284
Avg Volume (shares)
—
Shares Outstanding
82.1M
Next Earnings
2026-11-09

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-2.7
P/S Ratio
0.0x
EPS (TTM)
$-1.02
Dividend Yield
0.00%
Dilution (1yr)
+130.9%
LXEO logo

LEXEO THERAPEUTICS INC

LXEO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$109M▲ +3.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$99M▲ +21.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
76.4M▲ +130.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$55M▲ +$30M YoY
StockOtter · stockotter.space

About LEXEO THERAPEUTICS INC

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
40/100

Analyst Ratings

ⓘ
Consensus
Buy
16 analysts
Strong Buy8
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.